Abstract
In recent years, the incidence of non-Hodgkin's lymphoma (NHL) is on the rise, and diffuse large B-cell lymphoma (DLBCL) is the main type. Rituximab combined with chemotherapy has significantly improved the curative effect, but only 10% patients with relapsed and refractory DLBCL (R/R DLBCL) have the chance to cure by using limited methods. This article summarizes the pathogenesis and resistance mechanism of R/R DLBCL, individual selection in second-line therapy, the curative effect of new drugs and drugs combination, the application of targeted drug in different subtypes and different resistance mechanisms, immune checkpoint inhibitors and chimeric antigen receptor (CAR)-T cells, as well as the monitoring recurrence of R/R DLBCL. Key words: Lymphoma, large B-cell, diffuse; Therapeutics; Forecasting
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
